Bank of Queensland Ltd (ASX: BOQ), Harvey Norman Ltd (ASX: HVN) and Lynas Rare Earths Ltd (ASX: LYC) shares are in focus today amid a combination of analyst updates and shifting investor sentiment.

Let’s find out how these stocks are tracking, and what brokers expect next.

Brokers rate Lynas shares as a BUY

Lynas shares have fallen around 2% in Friday morning trade, to $14.10 a piece. The shares are now up around 15% for the year-to-date but are 17% below trading levels 12 months ago.

The downturn is down to a couple of factors which have combined to create headwinds for the ASX rare earths miner. Geopolitical volatility, higher costs, and investors taking their gains off the table after a strong rally earlier this year, have all dampened the share price.

But late last month the company posted a record FY26 profit and revenue as company growth continues to ramp up. Lynas reported a 76% increase in revenue and a 282% increase in EBITDA. 

The company also confirmed it is focused on ramping up new assets in FY27, and growing its global presence.

It looks like analysts are excited by Lynas’ potential. TradingView data shows the majority have a buy/strong buy rating on the shares. The average $19.57 target price implies a 39% upside, at the time of writing.

Brokers rate Harvey Norman shares as a HOLD

Harvey Norman shares are flat at $4.17 this morning. It’s been a difficult year for the retailer and its shares have shed 41% of their value so far in 2026. They’re also 43% lower than 12 months ago.

Harvey Norman has faced strong headwinds this year following renewed concerns about rising inflation and its impact on consumer spending. A tighter household budget means Australians have lowered their discretionary spending this year. 

The experts are on the fence about where the shares could go over the next 12 months. TradingView data shows six (out of 14) analysts have a hold rating on Harvey Norman. Another five rate the shares a sell/strong sell and three rate the shares as a buy/strong buy.

The $4.46 average target price implies a potential 7% upside ahead, at the time of writing.

Brokers rate BOQ shares as a SELL

BOQ shares have been relatively stable through September so far hovering between $6.50 and $6.70 a piece. It’s good news for investors after the ASX bank shares were caught up in a bank-sector-wide sell-off last month. 

At the time of writing the shares are also flat at $6.51 a piece. The shares are now down around 1% for the year-to-date and 9% lower than 12 months ago.

The bank is scheduled to post its FY26 results in three weeks time (on the 15th of October) and it looks like investors are sitting tight while they wait for an update on the bank’s revenue, net interest margin and final dividend call.

It looks like the shares are still considered to be trading above fair value. TradingView data shows the majority have a sell/strong sell rating on the shares. The $6.09 average target price implies a downside of around 6% at the time of writing. 

The post Buy, hold, sell: BOQ, Harvey Norman, Lynas shares appeared first on The Motley Fool Australia.

More reading

• How much superannuation do I need to earn $1,000 per week in passive income?
• Bank of Queensland shares hit a 52-week low in June. Are they cheap today?
• Downgrade alert! 5 ASX 200 shares downgraded by experts this week
• ASX retail shares are down 13% in 2026. Here’s what Morgan Stanley is worried about
• Starting with $20,000, how to build a portfolio generating $5,000 a year in passive income

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

After a rough couple of years, CSL Ltd (ASX: CSL) is getting some attention from Australia’s fund managers.

According to The Australian, new research from Morgan Stanley shows fundies been making some interesting changes to their portfolios.

And CSL is one of the stocks they’ve been buying.

CSL shares are currently down 0.40% to $178.41 in morning trade, following yesterday’s close of $179.12.

So, what are fund managers seeing in CSL?

CSL takes the top spot

Morgan Stanley’s research found healthcare extended its lead as the most favoured sector among Australian active fund managers during August.

CSL saw a significant increase in fund holdings, pushing it into the top spot among active positions.

An active overweight means a fund holds a larger weighting in a stock than it has in its benchmark index.

But it was a different story for some of the other bigger companies.

Managers remained underweight financials, particularly the major banks, although insurance stocks continued to attract interest.

In resources, managers increased their underweight position in BHP Group Ltd (ASX: BHP).

They also reduced their overweight exposure to Rio Tinto Ltd (ASX: RIO), while adding to gold holdings.

What’s behind the buying?

CSL’s latest results might help explain some of that interest, although there’s still plenty of work to do.

Its FY26 results showed revenue of US$15.8 billion, down 1% in constant currency.

Underlying NPATA fell 2% to US$3.1 billion, while restructuring costs and impairments contributed to a US$2.6 billion statutory loss.

But the business still managed to generate US$3.5 billion in operating cash flow.

CSL also completed an $1 billion share buyback during FY26 and announced another program worth up to $1.15 billion.

There’s also continued demand for immunoglobulin treatments, while sales of newer therapies Andembry and Hemgenix are growing.

Andembry generated US$240 million in sales during its first full year, while Hemgenix sales increased 25%.

What happens next for CSL shares?

CSL expects revenue to remain broadly unchanged in FY27, with underlying net profit forecast to grow approximately 5% in constant currency.

Its Behring division is targeting mid to single digit revenue growth, while Seqirus expects low to single digit growth.

However, Vifor remains a challenge, with revenue expected to decline approximately 25% amid generic competition and other product-related issues.

Brokers are also divided on where CSL shares could go from here.

Morgan Stanley has a $182 price target, while RBC Capital Markets is more optimistic at $213. Citi is more cautious at $160.

CSL’s AGM on 27 October will give investors another chance to hear how its recovery plans are progressing.

The post Fund managers are loading up on CSL shares. Here’s why appeared first on The Motley Fool Australia.

More reading

• Forget BHP and buy this ASX copper stock
• How much superannuation do I need to earn $2,000 per week in passive income?
• 6 ASX 200 shares scoring renewed buy calls this week
• Buy, hold, sell: BHP, CSL, and Westpac shares
• BHP shares fall as mining operations grind to a halt

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended BHP Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.5% to 8,662.4 points on Friday.

Brokers have lifted their ratings on several ASX 200 shares this week. 

Let’s take a look.

AMP Ltd (ASX: AMP)

The AMP share price is $2.66, down 0.2% today and up 60% over 12 months.

Over the past month, this ASX 200 financial share has ascended 11%.

Macquarie upgraded AMP shares to a buy rating on Tuesday.

The broker has a 12-month price target of $2.92.

This suggests a potential 10% upside ahead.

Evolution Mining Ltd (ASX: EVN)

The Evolution Mining share price is $13.66, down 0.5% today and up 33% over 12 months. 

Over the past month, this ASX 200 gold share has fallen 14%.

This week, Evolution announced its annual general meeting (AGM) will be held on Thursday 26 November.

UBS upgraded Evolution shares to a buy recommendation yesterday.

The broker raised its 12-month price target from $15.20 to $16.

This implies a potential 17% upside ahead.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is $15.79, up 0.3% today and up 3% over 12 months. 

Over the past month, this ASX 200 healthcare share has fallen 2%.

This week, Telix announced a merger with ITM Isotope Technologies Munich SE.

ITM is a global leader in therapeutic radioisotopes.

Telix Pharmaceuticals will acquire 100% of ITM for US$1.65 billion upfront.

RBC Capital upgraded Telix shares to a buy rating this week.

The broker lifted its 12-month price target from $19 to $21.

This suggests a potential 33% upside ahead.

Wesfarmers Ltd (ASX: WES)

The Wesfarmers share price is $73.99, up 0.2% today and down 20% over 12 months.

Over the past month, this ASX 200 consumer discretionary share has fallen 11%.

Morgan Stanley upgraded Wesfarmers shares to a hold rating this week.

The broker reduced its 12-month price target from $78 to $70.

This implies a potential 5% downside ahead.

Wesfarmers will conduct its AGM on Thursday 29 October.

Ramelius Resources Ltd (ASX: RMS)

The Ramelius Resources share price is $3.84, down 3% today and up 7% over 12 months.

Over the past month, this ASX 200 gold mining share has edged 3% lower.

This week, the miner released new FY27 guidance.

Ramelius Resources expects gold production of between 205,000 ounces and 225,000 ounces in FY27.

Its estimated all-in sustaining cost (AISC) is A$2,150 per ounce to A$2,350 per ounce.

The miner expects FY27 growth capital expenditure of A$480 million to A$570 million.

Canaccord Genuity upgraded Ramelius Resources shares to a buy call this week.

The broker raised its 12-month price target from $5.70 to $6.15.

This indicates potential capital gains of 56% over the next year. 

The post 5 ASX 200 shares upgraded by experts this week appeared first on The Motley Fool Australia.

More reading

• Super Retail Group vs Wesfarmers: Dividend showdown for Aussie investors
• 5 things to watch on the ASX 200 on Friday
• AMP vs Perpetual: Which ASX financial stock is better value?
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares
• GPT Group vs Dexus: Which ASX REIT is better value right now?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group, Telix Pharmaceuticals, and Wesfarmers. The Motley Fool Australia has recommended Macquarie Group, Telix Pharmaceuticals, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.